Lilly consigns shocking Xigris to critical care in investor- and state-backed biotech
This article was originally published in Scrip
Executive Summary
Lilly has decided that ten years of struggling with its sepsis drug, Xigris (drotrecogin alfa activated), is enough and now is the time to let someone else have a go. The Indianapolis-based company has licensed the US rights to the product to BioCritica, a newly formed private biotech based in central Indiana backed the private equity investors, Care Capital and NovaQuest Capital. The goal, Lilly says, is to attempt to put more resources behind US marketing of the underperforming Xigris.